Company intelligence / Profile preview
Abivax
Paris / Montpellier*, Île-de-France / Occitanie*, Franceabivax.gcs-web.com ↗
- Ownership
- Public · ABVX
- Employees
- ~27
- Development stage
- Phase 3
01
Overview
Obefazimod, an oral small molecule that enhances miR‑124 expression to regulate immune response, has shown positive results in Phase 2 trials for ulcerative colitis and rheumatoid arthritis. The pivotal global Phase 3 program (“ABTECT”) in moderately to severely active ulcerative colitis is ongoing with top-line induction data expected Q3 2025. A dose-ranging Phase 2b trial (“ENHANCE-CD”) for Crohn’s disease has IND clearance and will begin enrollment Q3 2024. Long-term extension studies are also underway.
The company continues to develop follow-on candidates from its proprietary chemical library.
Abivax collaborates with leading French academic institutions including CNRS, Institut Curie, and University of Montpellier.
- Therapeutic areas
- GastroenterologyImmunologyRheumatology
- Modalities
- Small molecules (notably obefazimod)MicroRNA modulation (miR‑124 enhancer)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
Collaborations with French National Center for Scientific Research (CNRS), Institut Curie, University of Montpellier; no major pharma partnerships publicly disclosed as of May 2025.
04
Financials
- Market cap
- $8.8B
- Total revenue
- $0
- Enterprise value
- $8.3B
Beyond the preview
Go deeper on Abivax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abivax.